Business Description
![Bristol-Myers Squibb Co Bristol-Myers Squibb Co logo](https://static.gurufocus.com/logos/0C0000070T.png?14)
Bristol-Myers Squibb Co
NAICS : 325412
SIC : 2834
ISIN : BRBMYBBDR000
Share Class Description:
BSP:BMYB34: Shs Unsponsored Brazilian Depository Receipt Repr 1 ShCompare
Compare
Traded in other countries / regions
BMY.USA0R1F.UKBMY.MexicoBRM.GermanyBMYB34.BrazilBMY.ArgentinaBMY.Peru1BMY.ItalyBMYS.AustriaBMY.Switzerland IPO Date
2011-08-30Description
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.17 | |||||
Equity-to-Asset | 0.17 | |||||
Debt-to-Equity | 3.48 | |||||
Debt-to-EBITDA | 10.79 | |||||
Interest Coverage | 5.58 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 1.23 | |||||
Beneish M-Score | -2.92 | |||||
WACC vs ROIC |
Growth Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 4.8 | |||||
3-Year EBITDA Growth Rate | 62.2 | |||||
3-Year EPS without NRI Growth Rate | 5.3 | |||||
3-Year FCF Growth Rate | 1.1 | |||||
3-Year Book Growth Rate | -5.1 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 92.36 | |||||
9-Day RSI | 82.52 | |||||
14-Day RSI | 74.68 | |||||
6-1 Month Momentum % | -3.7 | |||||
12-1 Month Momentum % | -22.19 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.11 | |||||
Quick Ratio | 0.99 | |||||
Cash Ratio | 0.37 | |||||
Days Inventory | 86.16 | |||||
Days Sales Outstanding | 67.49 | |||||
Days Payable | 104.78 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 4.29 | |||||
Dividend Payout Ratio | 2.22 | |||||
3-Year Dividend Growth Rate | 7.9 | |||||
Forward Dividend Yield % | 5.01 | |||||
5-Year Yield-on-Cost % | 6.3 | |||||
3-Year Average Share Buyback Ratio | 3.1 | |||||
Shareholder Yield % | 6.78 |
Profitability Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 75.71 | |||||
Operating Margin % | 15.98 | |||||
Net Margin % | -13.5 | |||||
FCF Margin % | 27.5 | |||||
ROE % | -22.16 | |||||
ROA % | -6.5 | |||||
ROIC % | 9.31 | |||||
ROC (Joel Greenblatt) % | -57.79 | |||||
ROCE % | -6.27 | |||||
Years of Profitability over Past 10-Year | 9 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 92.59 | |||||
PE Ratio without NRI | 47.39 | |||||
Shiller PE Ratio | 35.55 | |||||
PEG Ratio | 1.93 | |||||
PS Ratio | 2.24 | |||||
PB Ratio | 6.11 | |||||
Price-to-Free-Cash-Flow | 8.16 | |||||
Price-to-Operating-Cash-Flow | 7.43 | |||||
EV-to-EBIT | -32.88 | |||||
EV-to-Forward-EBIT | 35.48 | |||||
EV-to-EBITDA | 28.07 | |||||
EV-to-Forward-EBITDA | 29.61 | |||||
EV-to-Revenue | 3.28 | |||||
EV-to-Forward-Revenue | 3.03 | |||||
EV-to-FCF | 11.15 | |||||
Price-to-Projected-FCF | 0.73 | |||||
Price-to-DCF (Earnings Based) | 2.07 | |||||
Price-to-DCF (FCF Based) | 0.3 | |||||
Price-to-Median-PS-Value | 0.58 | |||||
Price-to-Peter-Lynch-Fair-Value | 3.13 | |||||
Earnings Yield (Greenblatt) % | -3.05 | |||||
FCF Yield % | 12.25 | |||||
Forward Rate of Return (Yacktman) % | 27.75 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Bristol-Myers Squibb Co Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil R$) | 223,965.752 | ||
EPS (TTM) (R$) | -15.67 | ||
Beta | -0.27 | ||
Volatility % | 25.87 | ||
14-Day RSI | 74.68 | ||
14-Day ATR (R$) | 5.024678 | ||
20-Day SMA (R$) | 226.0215 | ||
12-1 Month Momentum % | -22.19 | ||
52-Week Range (R$) | 203.1 - 310.58 | ||
Shares Outstanding (Mil) | 2,027.1 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Bristol-Myers Squibb Co Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Bristol-Myers Squibb Co Stock Events
Event | Date | Price(R$) | ||
---|---|---|---|---|
No Event Data |
Bristol-Myers Squibb Co Frequently Asked Questions
What is Bristol-Myers Squibb Co(BSP:BMYB34)'s stock price today?
The current price of BSP:BMYB34 is R$284.44. The 52 week high of BSP:BMYB34 is R$310.58 and 52 week low is R$203.10.
When is next earnings date of Bristol-Myers Squibb Co(BSP:BMYB34)?
The next earnings date of Bristol-Myers Squibb Co(BSP:BMYB34) is 2024-07-26.
Does Bristol-Myers Squibb Co(BSP:BMYB34) pay dividends? If so, how much?
The Dividend Yield %  of Bristol-Myers Squibb Co(BSP:BMYB34) is 4.29% (As of Today), Highest Dividend Payout Ratio of Bristol-Myers Squibb Co(BSP:BMYB34) was 2.22. The lowest was 0.27. And the median was 0.38. The  Forward Dividend Yield % of Bristol-Myers Squibb Co(BSP:BMYB34) is 5.01%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |